Company Overview
Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure. The company operates in the United States, Europe, and internationally. The company was incorporated in 2021 and is headquartered in Tucson, Arizona. Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard I, Llc.
Recent Developments
- Dec 2025 Revenue of $4.94M (+12.5% YoY); net profit $-27.00M.
- Trailing 12 Months Year-on-year growth — revenue +38.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.30% |
| 1 Year: | 38.60% |
Stock Price Performance
| 1 Year: | -98.12% |
| 6 Months: | -92.57% |
| 3 Months: | -67.35% |
| 1 Month: | +25.66% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 99.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PMI Picard Medical, Inc. PHARMA | 4.31 | -0.12 | $10.08M | 0.00% | - | - | 6.30% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 881.00K | - | 620.00K | 2.13M | 1.19M | 1.01M | 1.15M |
| Cost of Revenue | - | - | - | - | 978.00K | 2.26M | 1.32M | 598.00K | 875.00K |
| Gross Profit | - | -382.00K | -673.00K | - | -358.00K | -127.00K | -130.00K | 411.00K | 275.00K |
| Operating Expenses | - | - | - | - | 2.89M | 3.39M | 3.36M | 3.41M | 4.79M |
| Operating Income | - | -3.82M | -4.44M | - | -3.25M | -3.52M | -3.49M | -3.00M | -4.51M |
| EBITDA | - | - | - | - | -4.85M | -4.17M | -7.89M | -4.15M | -7.47M |
| Interest Expense | - | - | - | - | 555.00K | 2.43M | 2.40M | 7.00K | 5.00K |
| Pretax Income | - | - | - | - | -5.53M | -6.72M | -10.43M | -4.29M | -7.62M |
| Tax Provision | - | - | - | - | 31.00K | 0 | 0 | 4.00K | 0 |
| Net Income | -1.95M | -4.06M | -6.21M | - | -5.56M | -6.72M | -10.43M | -4.29M | -7.62M |
| Diluted EPS | - | - | - | - | -0.09 | -0.10 | -0.19 | - | -0.10 |
| R&D Expense | - | 940.00K | 961.00K | - | 808.00K | 743.00K | 951.00K | - | 1.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 4.11M | 5.04M | 4.39M | 4.94M |
| Cost of Revenue | 9.10M | 7.35M | 4.50M | 5.14M |
| Gross Profit | -4.99M | -2.31M | -112.00K | -204.00K |
| Operating Expenses | 6.08M | 13.19M | 13.60M | 13.05M |
| Operating Income | -11.07M | -15.50M | -13.71M | -13.26M |
| EBITDA | -10.61M | -14.85M | -17.46M | -21.06M |
| Interest Expense | 5.00K | 140.00K | 3.07M | 5.39M |
| Pretax Income | -11.16M | -15.57M | -21.07M | -26.97M |
| Tax Provision | 11.00K | -2.00K | -15.00K | 35.00K |
| Net Income | -11.17M | -15.57M | -21.05M | -27.00M |
| Diluted EPS | -0.18 | -0.25 | -0.33 | -0.75 |
| R&D Expense | - | - | 3.38M | 3.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 15.44M | 11.37M | 12.11M | 22.55M |
| Current Assets | 12.12M | 8.76M | 9.79M | 20.73M |
| Cash & Equivalents | 152.00K | 244.00K | 96.00K | 7.45M |
| Inventory | 7.33M | 6.89M | 8.12M | 7.30M |
| Receivables | 882.00K | 629.00K | 513.00K | 623.00K |
| Total Liabilities | 4.07M | 14.93M | 35.84M | 18.76M |
| Current Liabilities | 3.00M | 9.21M | 35.33M | 18.70M |
| Long Term Debt | - | 4.28M | - | - |
| Total Debt | 1.96M | 9.41M | 20.93M | 6.97M |
| Total Equity | 11.37M | -3.55M | -23.74M | 3.79M |
| Shares Outstanding | 72.06M | 72.06M | 72.06M | 73.70M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -10.72M | -10.63M | -11.87M | -15.67M |
| Investing Cash Flow | -37.00K | -9.00K | 0 | 0 |
| Financing Cash Flow | 5.52M | 10.84M | 11.74M | 27.08M |
| Capital Expenditure | -29.00K | -7.00K | - | - |
| Free Cash Flow | -10.75M | -10.64M | -11.87M | -15.67M |
| Net Change in Cash | -5.24M | 197.00K | -133.00K | 11.40M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | -121.3% | -45.8% | -2.6% | -4.1% |
| Operating Margin % | -269.1% | -307.4% | -312.3% | -268.4% |
| Net Margin % | -271.5% | -308.7% | -479.5% | -546.6% |
| ROE % | -98.2% | 438.3% | 88.7% | -712.6% |
| ROCE % | -89.0% | -717.0% | 59.1% | -344.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 2.15% | 50.37K | $255.87K |
| 2 | AQR Capital Management, LLC | 1.83% | 42.90K | $217.93K |
| 3 | Jane Street Group, LLC | 1.18% | 27.54K | $139.92K |
| 4 | IEQ Capital, LLC | 0.25% | 5.81K | $29.52K |
| 5 | Renaissance Technologies, LLC | 0.15% | 3.45K | $17.52K |
| 6 | FMR, LLC | 0.13% | 3.02K | $15.34K |
| 7 | UBS Group AG | 0.11% | 2.50K | $12.72K |
| 8 | Cerity Partners LLC | 0.10% | 2.31K | $11.73K |
| 9 | Wealth Enhancement Advisory Services, LLC | 0.06% | 1.52K | $7.71K |
| 10 | Mariner, LLC | 0.06% | 1.52K | $7.72K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PMI
UAE shares jump as PMI shows solid growth in August - Reuters
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQR2M1d1J6c0hHYVllcEFySjlIUFdUbVYxZXdtTmczWDhxYktaa2J0RFhpcUJTVFZlOXJOX0FSQl9zQV83Y1g5S19kdjRUMG5PQUR3VDNrcnhoZFI4cWxjV1ZSYnU3VFROYi1kcmMyaldwQnFRU3NGT2ZfQ3NrbEtLS2FWQ280dldsZGZTY3…
Every 50 Picard Medical shares are expected to become one - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOaTF0NnltU19jSlRoRkpxWjFSVVk2SXhnN0MwWWpqTDJxZThYM250a2pCcVZQeldBNlg0UEhEMWh3bkZrZDFyc2FZSEk1STBKVUNuNEotMDFnQ2ppUGF2MEdDQjRFeDZaZHUwQVZPV0JQdnItXy1ERXBGX1pnLXFzR2dsT1hfOWZPZGRPZn…
US Stock Market Today: S&P 500 Futures Edge Lower As Strong PMI Complicates Fed Path - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNMEZabXdzSjFzN01CeHM5a3Z1OGtvMFQzX1FQS3FORDJkZHprMzZFa2p4VnJmSHBGQTd1S1NYMFMybXd6MDZJbGRKVm02NmlRd3RQUnZxb2pLa3ZfVzdBVGwweWdxazRqdW9tNTVwaWJLc2JVRzRQM3pPdVd6c3cza3FubmZ4WTNSbG4xTk…
PMI - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTE0wMWVTZmYxV0tZYlFvX0Rialp5NnNJVWFEbUMxc3BZZWxGandfY0gzR3U1aEpYZ25tMHRXX1RRVHhfYzVo?oc=5" target="_blank">PMI</a> <font color="#6f6f6f">Finviz</font>…
PMI Stock Pulls Back As Losses Weigh On Outlook - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE13a3otMVdpcHJKVXRMQW5pM0gtYTJVeV8zMVJDS3Nla0NkSEhfUHljUmI3YWVrenliUWxMS1lCbFhiaFI2alhjMTJyUVBHb1RHblhncU9rU2VFNFdVRDRFdm9KV0xnXy1hNjZVUzROUUdhSUJCenpUMC1IMA?oc=5" target="_blank">P…
Stock Market at Risk as NVDA, FOMC Minutes, and PMI Data Loom - tastylive
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNLUE3Z2JFZko4SGpVVnQ1OWZTdHpDT0c1X1h3REtQQktXOTlqdjhvV29LOVZYT2ZyQXdMX05tbjNZYzk3OVI1UEdkaWdRTzR1R21hck5QQU1WU25ncXp1TnUwU0pqblVpR2p2YThmRGpyWXB1WUFTNDVvb0FwRUhPU3Z5LUZRM3BlbUJsOW…
PMI — Frequently Asked Questions
What is the current share price of Picard Medical, Inc. (PMI)?
As of 2026-09-19 21:16 PDT, Picard Medical, Inc. (PMI) trades at $4.31 on NYSE American. Its 52-week range is $3.03 to $660.00.
What is the market capitalisation of PMI?
Picard Medical, Inc. (PMI) has a market capitalisation of $10.08M on NYSE American.
What is the P/E ratio of PMI?
PMI trades at a trailing price-to-earnings (P/E) ratio of -0.12. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 6.08.
Is PMI a good stock to buy?
This page provides a data-driven analysis of Picard Medical, Inc. (PMI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.